Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

Completed · Phase 2

Conditions studied: Immunoglobulin G4 Related Disease

In brief

This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental: rilzabrutinib with glucocorticoids and (2) Active Comparator: glucocorticoids only.

Key facts

Study ID

NCT04520451

Run by

Principia Biopharma, a Sanofi Company

People needed

27

Starts

2020-08-22

Expected to finish

2024-10-15

Last updated by the study team

2025-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigational Site Number 84019 — Stanford, California, United States
• Investigational Site Number 84016 — Boston, Massachusetts, United States
• Investigational Site Number 84018 — Detroit, Michigan, United States
• Investigational Site Number 84030 — New York, New York, United States
• Investigational Site Number 84036 — Portland, Oregon, United States
• Investigational Site Number 12403 — Vancouver, Canada
• Investigational Site Number 25013 — Marseille, France
• Investigational Site Number 38016 — Milan, Italy
• Investigational Site Number 72415 — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.